|
1
|
Deng Y, Chang C and Lu Q: The inflammatory
response in psoriasis: A comprehensive review. Clin Rev Allergy
Immunol. 50:377–389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nestle FO, Kaplan DH and Barker J:
Psoriasis. N Engl J Med. 361:496–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weinstein GD, McCullough JL and Ross P:
Cell proliferation in normal epidermis. J Invest Dermatol.
82:623–628. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang T, Lin X, Meng X and Lin M:
Phosphoinositide-3 kinase/protein kinase-B/mammalian target of
rapamycin pathway in psoriasis pathogenesis. A potential
therapeutic target? Acta Derm Venereol. 94:371–379. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sticozzi C, Belmonte G, Cervellati F, Di
Capua A, Maioli E, Cappelli A, Giordani A, Biava M, Anzini M and
Valacchi G: Antiproliferative effect of two novel COX-2 inhibitors
on human keratinocytes. Eur J Pharm Sci. 49:133–141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhatt KV, Spofford LS, Aram G, McMullen M,
Pumiglia K and Aplin AE: Adhesion control of cyclin D1 and p27Kip1
levels is deregulated in melanoma cells through BRAF-MEK-ERK
signaling. Oncogene. 24:3459–3471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sezer E, Böer-Auer A, Cetin E, Tokat F,
Durmaz E, Sahin S and Ince U: Diagnostic utility of Ki-67 and
Cyclin D1 immunostaining in differentiation of psoriasis vs. other
psoriasiform dermatitis. Dermatol Pract Concept. 5:7–13. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu W, Li J, Su J, Li J, Li J, Deng B, Shi
Q, Zhou Y and Chen X: FOS-like antigen1 is highly expressed in
human psoriasis tissues and promotes the growth of HaCaT cells in
vitro. Mol Med Rep. 10:2489–2494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lavoie JN, Rivard N, L'Allemain G and
Pouysségur J: A temporal and biochemical link between growth
factor-activated MAP kinases, cyclin D1 induction and cell cycle
entry. Prog Cell Cycle Res. 2:49–58. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Palmero I and Peters G: Perturbation of
cell cycle regulators in human cancer. Cancer Surv. 27:351–367.
1996.PubMed/NCBI
|
|
12
|
Sheaff RJ, Groudine M, Gordon M, Roberts
JM and Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes
Dev. 11:1464–1478. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Flatt PM, Tang LJ, Scatena CD, Szak ST and
Pietenpol JA: p53 regulation of G(2) checkpoint is retinoblastoma
protein dependent. Mol Cell Biol. 12:4210–4213. 2000. View Article : Google Scholar
|
|
14
|
Gire V and Dulic V: Senescence from G2
arrest, revisited. Cell Cycle. 14:297–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rashmi R, Rak KS and Basavaraj KH: A
comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol.
34:658–663. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schaller G and Meyer-Hermann M: A modeling
approach towards epidermal homoeostasis control. J Theor Biol.
247:554–573. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abou EL-Ela M, Nagui N, Mahgoub D,
El-Eishi N, Fawzy M, El-Tawdy A, Abdel Hay R and Rashed L:
Expression of cyclin D1 and p16 in psoriasis before and after
phototherapy. Clin Exp Dermatol. 35:781–785. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miracco C, Pellegrino M, Flori ML, Vatti
R, Materno M and Andreassi L: Cyclin D1, B and A expression and
cell turnover in psoriatic skin lesions before and after
cyclosporin treatment. Br J Dermatol. 143:950–956. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
LaPak KM and Burd CE: The molecular
balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res.
12:167–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim WY and Sharpless NE: The regulation of
INK4/ARF in cancer and aging. Cell. 127:265–275. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lukas J, Parry D, Aagaard L, Mann DJ,
Bartkova J, Strauss M, Peters G and Bartek J:
Retinoblastoma-protein-dependent cell-cycle inhibition by the
tumour suppressor p16. Nature. 375:503–506. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sherr CJ: The Pezcoller lecture: Cancer
cell cycles revisited. Cancer Res. 60:3689–3695. 2000.PubMed/NCBI
|
|
23
|
Brasanac D, Stojkovic-Filipovic J, Bosic
M, Tomanovic N and Manojlovic-Gacic E: Expression of G1/S-cyclins
and cyclin-dependent kinase inhibitors in actinic keratosis and
squamous cell carcinoma. J Cutan Pathol. 43:200–210. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yazici AC, Karabulut AA, Ozen O, Ekşioğlu
M and Ustün H: Expression of p53 in lesions and unaffected skin of
patients with plaque-type and guttate psoriasis: A quantitative
comparative study. J Dermatol. 34:367–374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Florence ME, Massuda JY, Soares TC,
Stelini RF, Poppe LM, Bröcker EB, Metze K, Cintra ML and de Souza
EM: p53 immunoexpression in stepwise progression of cutaneous
squamous cell carcinoma and correlation with angiogenesis and
cellular proliferation. Pathol Res Pract. 211:782–788. 2015.
View Article : Google Scholar : PubMed/NCBI
|
